Identification of *APN2*, the *Saccharomyces cerevisiae* homolog of the major human AP endonuclease *HAP1*, and its role in the repair of abasic sites

Robert E. Johnson, Carlos A. Torres-Ramos, Tadahide Izumi, Sankar Mitra, Satya Prakash, and Louise Prakash¹

Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, Texas 77555-1061 USA

Abasic (AP) sites arise in DNA through spontaneous base loss and enzymatic removal of damaged bases. *APN1* encodes the major AP-endonuclease of *Saccharomyces cerevisiae*. Human *HAP1* (*REF1*) encodes the major AP endonuclease which, in addition to its role in DNA repair, functions as a redox regulatory protein. We identify *APN2*, the yeast homolog of *HAP1* and provide evidence that *Apn1* and *Apn2* represent alternate pathways for repairing AP sites. The *apn1Δ apn2Δ* strain displays a highly elevated level of MMS-induced mutagenesis, which is dependent on the *REV3*, *REV7*, and *REV1* genes. Our findings indicate that AP sites are highly cytotoxic and mutagenic in eukaryotes, and that the *REV3*, *REV7*-encoded DNA polymerase ζ mediates the mutagenic bypass of AP sites.

[Key Words: *APN2*; *APN1*; base excision repair; mutagenic bypass; yeast]

Received June 30, 1998; revised version accepted August 14, 1998.

Abasic (AP) sites arise in DNA at a significant rate by spontaneous hydrolysis of the *N*-glycosylic bond. Extrapolating from the rate of depurination occurring in vitro under physiological conditions, it has been estimated that as many as 10⁴ purines are lost spontaneously in a human cell per day (Lindahl and Nyberg 1972). AP sites are also formed in DNA as intermediates in base excision repair (BER).

Two major class II AP Endos have been identified in *Escherichia coli*. exonuclease III, the product of the *xth* gene, is a constitutive and abundant enzyme representing ~90% of the total AP activity, and endonuclease IV, encoded by the *nfo* gene, is an inducible activity representing 10%–50% of the activity in uninduced or induced cells, respectively. Both enzymes also possess a 3'-phosphatase, and a 3'-phosphodiesterase activity that can remove 3'-terminal groups formed in DNA by free radical attack or by the action of β -lyase activity associated with some of the DNA glycosylases (Dempfle and Harrison 1994; Seeberg et al. 1995; Wallace 1997).

Homologs of *E. coli* exonuclease III and endonuclease IV (Exo III, Endo IV) have been identified in eukaryotes.

In *Saccharomyces cerevisiae*, *APN1* encodes the major AP Endo, and it shares extensive homology with Endo IV (Popoff et al. 1990). Like its *E. coli* counterpart, *Apn1* is a class II AP endonuclease, and it has 3'-diesterase, and 3'-phosphatase activities (Johnson and Dempfle 1988a,b). A homolog of *E. coli* Exo III has not yet been identified in yeast. In contrast to yeast, Exo III homologs have been identified from mammalian and other sources. The enzyme from humans, variously known as HAP1, APE, Ref-1, or Apex, has a robust class II AP endonuclease activity, but its 3'-phosphodiesterase and 3'-phosphatase activities are relatively weak (Chen et al. 1991; Winters et al. 1994). Interestingly, HAP1 also functions as a regulatory protein, stimulating the DNA-binding activity of AP-1 proteins, such as c-Jun and c-Fos, by a redox-dependent mechanism (Xanthoudakis and Curran 1992). The stimulatory effect of HAP1 on Jun and Fos is mediated through reduction of a conserved cysteine residue present in the DNA-binding domain of each protein (Abate et al. 1990; Xanthoudakis et al. 1992). HAP1 also stimulates the DNA-binding activity of other redox regulated transcription factors, including p53 (Xanthoudakis et al. 1992; Jayaraman et al. 1997). The DNA repair and redox activities of HAP1 reside in distinct regions of the protein and can function independently of one another (Walker et al. 1993; Xanthoudakis et al. 1994). HAP1 is

¹Corresponding author.
E-MAIL lprakash@scms.utmb.edu; FAX (409) 747-8608.

essential for the early embryonic development of mice, as mice lacking a functional *HAP1* gene die shortly after implantation (Xanthoudakis et al. 1996). Because sequences containing both the DNA repair and redox regulatory activities have been disrupted in these mutant mice, it is not known whether one or both of these activities are necessary for embryonic development.

Here we identify a homolog of Exo III/*HAP1* in *S. cerevisiae*, which we have named *APN2*, and examine the effects of *apn1Δ* and *apn2Δ* mutations on viability, mutagenesis, and the repair of AP sites.

Results

APN2 is a member of the Exo III family of AP endonucleases

The *S. cerevisiae* *APN2*-encoded protein is homologous to *E. coli* Exo III (Xth), human *HAP1*, and to the other related enzymes from *Drosophila*, *Arabidopsis*, and other bacterial species (Fig. 1). The *HAP1* protein from residues 62–318 retains all of the DNA repair activities (Walker et al. 1993; Xanthoudakis et al. 1994; Izumi and Mitra 1998). This region of ~250 residues is highly con-

served among *HAP1*, *Apn2*, *Exo III*, and other members of the family (Fig. 1A,B). In this region, *Apn2* shares 33% similar and 21% identical residues with *HAP1*, and 26% similar and 19% identical residues with the *E. coli* Xth protein.

From the x-ray crystal structure of *Exo III*, residues Asp-229 and His-259 have been proposed to mediate catalysis, and Glu-34 to bind a metal ion and to facilitate catalysis (Mol et al. 1995). *HAP1* shares considerable structural similarity to *Exo III* (Gorman et al. 1997). Mutational inactivation of the corresponding *HAP1* active site residues Asp-283, His-309, and Glu-96 to alanine has indicated a critical role of these residues in catalysis (Barzilay et al. 1995). These residues and the sequences flanking them have been very highly conserved in *Apn2* and in the other members of this nuclease family (Fig. 1A,B). *Apn2* and its counterpart from *Schizosaccharomyces pombe* have a carboxy-terminal domain that is absent in the other homologs (Fig. 1B). This region of the protein may be involved in species-specific protein-protein interactions.

The amino-terminal 61 residues of *HAP1* are absent in *Exo III*, and this region is not conserved in *Apn2* (Fig. 1A). This amino-terminal region of *HAP1* is important for redox activity but not for DNA repair functions. The

Figure 1. *Apn2* is a member of the Exo III/*HAP1* family of proteins. (A) Alignment of human *HAP1*, *S. cerevisiae* *Apn2*, and *E. coli* Exo III (Xth) proteins. Identical and highly conserved residues are highlighted. Amino acid positions are indicated by numbers in parentheses. The conserved residues thought to be involved in catalytic activity (Glu-96, Asp-283, and His-309 in *HAP1* protein) are indicated by arrows. The Cys-65 residue in *HAP1* essential for the redox activity is circled and indicated by an asterisk. (B) Schematic alignment of Exo III-type nucleases from various organisms. Boxes represent primary amino acid sequence. Narrow regions indicate unique sequences, whereas larger, shaded, or stippled regions indicate regions of homology among the proteins. The different shades within the boxes indicate independent domains; spaces indicate gaps that were introduced to optimize alignment of the proteins. Protein lengths are indicated by numbers at right. Positions of the highly conserved amino acid sequences QE(T/L/I)K, R(L/I)D, and SDH(C/A)P are indicated. Positions of the redox cysteine residue in human *HAP1*, and of cysteine residues present at the corresponding position in *Drosophila* RRP and *Arabidopsis thaliana* ARP proteins are indicated by the letter C within the alignments.

Cys-65 residue present in HAP1 is essential for redox activity, as replacement of this residue with alanine inhibits the ability of HAP1 to stimulate Jun DNA binding (Walker et al. 1993; Xanthoudakis et al. 1994). This cysteine residue is not conserved in Exo III or Apn2. Exo III has no redox activity (Walker et al. 1993), and Apn2 is likely to be devoid of this activity.

APN2 is not essential for growth or survival

As previously reported (Ramotar et al. 1991), deletion of *APN1* has no effect on the growth or viability of yeast cells. We have observed no effect of the *apn2Δ* mutation on viability or growth, and the *apn1Δ apn2Δ* double mutant also grows normally (data not shown). Because AP sites are noncoding, we determined whether spontaneous mutations arise at a much higher rate in the strains deleted for both of the *APN* genes. Deletion of *APN1* increased the rate of *can1^r* mutations 3.5-fold, a result similar to that reported previously (Ramotar et al. 1991). The rate of spontaneous *can1^r* mutations in the *apn2Δ* strain was the same as in the wild-type strain, and the *apn1Δ apn2Δ* strain exhibited the same level of spontaneous mutability as the *apn1Δ* strain (data not shown).

The apn2Δ mutation enhances the sensitivity of the apn1Δ strain to alkylation damage

To determine the relative contribution of the *APN1* and *APN2* genes to the repair of AP sites, we tested the sensitivity of the *apn1Δ*, *apn2Δ*, and *apn1Δ apn2Δ* mutant strains to the alkylating agent MMS. MMS alkylates the bases in DNA, particularly adenine at the N3 position (3MeA) and guanine at the N7 position (7MeG). The alkylated bases are removed by the action of *N*-methylpurine DNA glycosylases (MPG), which act on 3MeA and 7MeG and also on a variety of other alkylated bases (Roy et al. 1994; Bjoras et al. 1995). The AP sites resulting from DNA glycosylase action would be acted on by the Apn1 or Apn2 proteins. As shown in Figure 2A, and as reported previously (Ramotar et al. 1991), the *apn1Δ* mutant strain exhibits moderate sensitivity to MMS. The MMS sensitivity of the *apn2Δ* strain is similar to that of the wild-type strain. The *apn1Δ apn2Δ* strain, however, displays an extremely enhanced MMS sensitivity, suggesting that Apn1 and Apn2 compete for the repair of AP sites, and in the absence of both AP endonucleases, AP sites remain in DNA and result in cell lethality.

To confirm that the extreme MMS-sensitive phenotype of the *apn1Δ apn2Δ* strain was, in fact, attributable to deletions of these two genes, we constructed low copy *CEN* vectors carrying the wild-type *APN1* or the *APN2* gene, and transformed these plasmids into the *apn1Δ apn2Δ* strain to test for complementation. As expected, introduction of the *APN1* plasmid into the *apn1Δ apn2Δ* strain restored MMS survival to wild-type levels, whereas introduction of the *APN2* plasmid conferred MMS resistance to the level equivalent to that seen in the *apn1Δ* mutant strain (data not shown).

Figure 2. Enhanced MMS sensitivity and MMS mutagenesis in the *apn1Δ apn2Δ* strain. (A) MMS sensitivity of various yeast strains. Cells grown overnight in YPD medium were treated with MMS at the concentrations indicated for a 20-min period. Appropriate dilutions were spread onto YPD plates. Each curve represents the average of two to three experiments for each strain. (●) EMY74.7, wild type (*APN1 APN2*); (□) YRP190, *apn1Δ*; (△) YRP263, *apn2Δ*; (○) YRP269, *apn1Δ apn2Δ*. (B) MMS-induced mutations at the *CAN1* locus. Cells grown overnight in YPD medium were treated with MMS at the concentrations indicated for a 20-min period. Appropriate dilutions were spread onto YPD plates for viability determinations and onto synthetic complete medium lacking arginine and containing canavanine for the determination of *CAN1^S* to *can1^r* mutagenesis. Each curve represents the average of two to three experiments for each strain. (●) EMY74.7, wild type (*APN1 APN2*); (□) YRP190, *apn1Δ*; (△) YRP263, *apn2Δ*; (○) YRP269, *apn1Δ apn2Δ*.

Enhanced MMS-induced mutagenesis in the apn1Δ apn2Δ strain

Because AP sites are noncoding, they would present a block to the DNA replicational machinery. Replication through such sites could occur by a mutagenic process in which DNA polymerase misincorporates a nucleotide opposite such a lesion, or these sites may be bypassed by error-free postreplicative repair processes in which the gap left opposite the AP site is filled in either by a 'copy choice' type of DNA synthesis in which the undamaged sister duplex is used as the template for copying the missing information (Higgins et al. 1976) or by a recombinational mechanism. To evaluate the extent to which AP sites are mutagenic in eukaryotes, we determined the rate of *CAN1^S* to *can1^r* mutations in MMS-treated wild-type, *apn1Δ*, *apn2Δ*, and *apn1Δ apn2Δ* strains (Fig. 2B). The incidence of MMS-induced *can1^r* mutations was the same in the wild-type and *apn2Δ* strains, and was elevated only slightly in the *apn1Δ* strain. In contrast, the frequency of MMS-induced *can1^r* mutations rose sharply in the *apn1Δ apn2Δ* strain. For instance, whereas treatment with 0.1% MMS produced 250–500 *can1^r* mutants per 10⁷ viable cells in the wild-type, *apn1Δ*, and *apn2Δ* strains, the *can1^r* mutation frequency rose to 19,000 per

10^7 cells in the *apn1Δ apn2Δ* strain (Fig. 2B). Introduction of the *APN1* or the *APN2* gene carried on a *CEN* plasmid into the *apn1Δ apn2Δ* strain lowered MMS mutagenesis to levels seen in the wild-type and the *apn1Δ* strain, respectively (data not shown). These findings provide the first clear evidence of the high mutagenic potential of unrepaired AP sites in eukaryotes.

Defective repair of MMS-induced DNA damage in the *apn1Δ apn2Δ* mutant strain

The greatly enhanced MMS sensitivity of the *apn1Δ apn2Δ* mutant strain suggested that both Apn1 and Apn2 function in the removal of AP sites from DNA. To directly assess the role of these nucleases in the repair of AP sites, we examined the level of AP sites in MMS-treated wild-type, *apn1Δ*, *apn2Δ*, and *apn1Δ apn2Δ* mutant strains by sedimentation of DNA in alkaline sucrose gradients. Because NaOH hydrolyzes the phosphodiester bond near each AP site, the size reduction in DNA observed on sedimentation in alkaline sucrose gradients is a good measure of the AP sites present. Yeast cells were treated with 0.1% MMS for 20 min, and the sedimentation profile of DNA was evaluated immediately following this treatment, and following incubation of these cells for an additional 1 or 2 hr to allow time for DNA repair to occur (Fig. 3). In all of the strains, DNA from MMS-treated cells sediments toward the top of the gradient, indicating the presence of AP sites. The sedimentation pattern of DNA obtained from wild-type or *apn2Δ* cells that had been incubated for 1 hr following MMS treatment was the same as that of DNA from untreated control cells, indicating proficient repair of AP sites in both these strains during the 1-hr period (Fig. 3A,C). As previously reported (Ramotar et al. 1991), removal of AP sites was less efficient in the *apn1Δ* strain. DNA obtained from MMS-treated *apn1Δ* cells that were allowed a 1-hr repair period sedimented at a slower rate than DNA from untreated cells. The size of DNA increased in cells that had been incubated for 2 hr after MMS treatment, but even after this longer repair period, DNA was not fully restored to normal size (Fig. 3B). The removal of AP sites was severely impaired in the *apn1Δ apn2Δ* mutant strain, as DNA from MMS-treated *apn1Δ apn2Δ* cells allowed a 2-hr repair period sedimented only slightly faster than DNA from cells that were treated with MMS but allowed no repair period (Fig. 3D).

Requirement of REV genes in mutagenic bypass of AP sites

Recent in-vitro studies with mammalian DNA polymerase δ (Pol δ) and proliferating cell nuclear antigen (PCNA) have indicated that PCNA allows Pol δ to replicate past an AP site present in the template strand, resulting in the formation of full-length product (Mozzherin et al. 1997). As expected from the A-rule (Strauss 1991), fully extended primers incorporated predominantly dAMP opposite the template lesion. Exten-

Figure 3. Alkaline sucrose gradient analysis of DNA from cells treated with 0.1% MMS for 20 min. (A) YRP276, wild type (*APN1 APN2*). (B) YRP210, *apn1Δ*. (C) YRP291, *apn2Δ*. (D) YRP292, *apn1Δ apn2Δ*. (○) Untreated cells; (●) cells treated with MMS for 20 min; (▲) cells treated with MMS for 20 min, and then given a 1-hr repair period; (△) cells treated with MMS for 20 min, and then given a 2-hr repair period.

sive genetic studies in yeast, however, have provided evidence for the involvement of *REV3*, *REV7*, and *REV1* genes in mutagenesis induced by UV light (Lawrence and Hinkle 1996). More recent biochemical studies have indicated that Rev3 and Rev7 constitute two subunits of DNA Pol ζ , which has the ability to replicate past a thymine cis-syn cyclobutane dimer (Nelson et al. 1996b). Rev1 has a deoxycytidyl transferase activity, and it transfers a dCMP residue to the 3' end of a primer in a template-dependent reaction. Interestingly, the enzyme efficiently inserts dCMP opposite an AP site, producing a terminus that can be extended by Pol ζ (Nelson et al. 1996a).

The availability of the *apn1Δ apn2Δ* strain has provided us the opportunity to test whether mutagenic bypass of AP sites is mediated by the Rev proteins. To examine this, we incorporated the *rev3Δ*, *rev7Δ*, and *rev1Δ* mutations in the *apn1Δ apn2Δ* strain, and examined the incidence of MMS-induced mutations. As shown in Figure 4, the *rev3Δ*, *rev7Δ*, or *rev1Δ* mutations did not enhance the MMS sensitivity of *apn1Δ apn2Δ* strain, but, interestingly, no MMS-induced *can1^r* mutations were recovered in any of these *apn1Δ apn2Δ revΔ* mutant strains.

Figure 4. Requirement of *REV* genes for MMS-induced mutagenesis in the *apn1Δ apn2Δ* strains. Methods are as described in the legend to Fig. 2. (A) MMS sensitivity of yeast strains. (●) EMY74.7, wild type (*APN1 APN2*); (○) YRP269, *apn1Δ apn2Δ*; (△) YREV1.15, *rev1Δ*; (▴) YREV3.15, *rev3Δ*; (▽) YREV7.1, *rev7Δ*; (▲) YREV1.13, *apn1Δ apn2Δ rev1Δ*; (□) YREV3.40, *apn1Δ apn2Δ rev3Δ*; (▽) YREV7.4, *apn1Δ apn2Δ rev7Δ*. (B) MMS-induced mutations of *CAN1^s* to *can1^F*. (○) YRP269, *apn1Δ apn2Δ*; (▲) YREV1.13, *apn1Δ apn2Δ rev1Δ*; (□) YREV3.40, *apn1Δ apn2Δ rev3Δ*; (▽) YREV7.4, *apn1Δ apn2Δ rev7Δ*.

These results indicate that mutagenic bypass of AP sites is controlled by Pol ζ and its accessory factors.

Discussion

AP sites are one of the most common lesions in DNA. To define the pathways for the repair of AP sites in eukaryotes, here we identify yeast *APN2*, a homolog of *E. coli* Exo III and human *HAP1*. Deletion of *APN2* has no effect on cell viability or growth, and the *apn1Δ apn2Δ* mutant also grows normally. Sensitivity to MMS is not affected by the *apn2Δ* mutation, but the *apn1Δ apn2Δ* strain displays a much higher level of sensitivity to MMS than the *apn1Δ* strain, which is only moderately sensitive to this DNA-damaging agent. Consistent with this observation, the *apn1Δ apn2Δ* mutant is highly deficient in the removal of AP sites, as determined by alkaline sucrose gradient sedimentation of DNA obtained from MMS-treated cells. These results provide strong evidence for a role of Apn2 in the removal of AP sites, and they indicate that Apn1 and Apn2 represent alternate ways of removing AP sites.

The identification of Apn2 and the demonstration of its involvement in the repair of AP sites in yeast attests to the high degree of conservation of pathways for repairing AP sites among prokaryotes and eukaryotes. Therefore, Exo III in *E. coli*, Apn2 in *S. cerevisiae*, and HAP1 in humans, all function in the removal of AP sites. Even though no Endo IV/Apn1 homolog has yet been identified in humans and higher eukaryotes, such an activity is likely to be present in there as well. It is of some interest to note that although the enzymes for removing

AP sites, as well as many of the DNA *N*-glycosylases, have been conserved between prokaryotes and eukaryotes, no such conservation exists among the components of the nucleotide excision repair machinery.

Apn1 accounts for >90% of the class II AP endonuclease/3'-diesterase activity in wild-type yeast cell extracts, suggesting that the activity encoded by *APN2* is relatively minor. This is consistent with the observation that deletion of *APN1* increases the rate of spontaneous mutations as well as MMS sensitivity, but deletion of *APN2* has no effect on these phenotypes. In the absence of Apn1, however, cells rely on the repair function of Apn2, as deletion of both the *APN1* and *APN2* genes elicits a large increase in MMS sensitivity and confers a severe reduction in the ability to remove AP sites. A class II AP endonuclease and 3'-phosphodiesterase activity has been recently partially purified from *apn1Δ S. cerevisiae* cells. Unlike Apn1, but similar to Exo III, this activity is strongly dependent on Mg^{2+} (Sander and Ramotar 1997). *APN2* may encode this activity.

The high level of deficiency in the removal of AP sites in the *apn1Δ apn2Δ* strain would predict that spontaneously arising AP sites would accumulate in this strain. It is therefore somewhat surprising that simultaneous inactivation of the *APN1* and *APN2* genes has no effect on cell viability or growth, and spontaneous mutability is increased only a few fold in the *apn1Δ apn2Δ* strain. On infliction of additional DNA damage, however, as on treatment with MMS, *apn1Δ apn2Δ* cells suffer a drastic reduction in survival, and they display a sharp rise in mutagenesis. We interpret these observations as follows. In normally growing *apn1Δ apn2Δ* cells, the AP sites resulting from spontaneous base loss can be efficiently handled by postreplicative bypass processes, and a majority of these act in an error-free manner. In MMS-treated cells, however, the rising level of AP sites is handled by error-free as well as mutagenic bypass processes, resulting in a steep rise in the incidence of mutations in the surviving *apn1Δ apn2Δ* cells and cell death occurs if all the bypass processes are saturated.

Even though in vitro studies have indicated that mammalian DNA Pol δ , in concert with PCNA, can efficiently bypass AP sites (Mozzherin et al. 1997), our genetic studies provide evidence for the requirement of *REV3* and *REV7* encoded DNA Pol ζ and of Rev1 protein in mutagenic bypass of AP sites. Deletion of any of these *REV* genes in the *apn1Δ apn2Δ* strain, however, causes no significant enhancement of MMS sensitivity, suggesting that mutagenic bypass by the *REV3* system makes only a minor contribution to cell survival and that a majority of AP sites are bypassed in an error-free manner. Because AP sites would represent one of the most frequently formed DNA lesions in mammalian cells (Lindahl and Nyberg 1972), however, DNA Pol ζ -mediated mutagenic bypass of AP sites may make a significant contribution to mutagenesis, and to tumorigenesis and carcinogenesis. The identification of *REV3* and *REV7* counterparts in humans (Lawrence and Hinkle 1996; Gibbs et al. 1998) supports such a possibility.

In contrast to the absence of any effect on cell viability

of the *apn2Δ* mutation either alone or when combined with the *apn1Δ* mutation, mice lacking a functional *HAP1* (*REF1*) gene die during embryonic development, following blastocyst formation (Xanthoudakis et al. 1996). This lethality may arise from a deficiency in the repair of AP sites or of oxidative damage, or from the inactivation of the redox regulatory function, or from the combined effects of these deficiencies. The redox activity of HAP1 protein resides in the amino-terminal domain, and cysteine 65 is essential for this function. Because neither the amino-terminal sequence nor the cysteine 65 residue have been conserved in Apn2, this protein may have no role in redox regulation. Our observations with the yeast *apn1Δ apn2Δ* mutant may suggest that embryonic lethality of *hap1*^{−/−} mice results from a deficiency in the redox regulatory function and not from the inactivation of the DNA repair function of HAP1.

Materials and methods

Identification of APN2

To identify the yeast homolog of the human AP endonuclease HAP1, the HAP1 protein sequence (GenBank accession no. M92444) was used to search for homologs in the *S. cerevisiae* nonredundant protein data set at the Saccharomyces Genome Database using the BLAST program (Altschul et al. 1990). The *S. cerevisiae* open reading frame (ORF) designated YBL019W (accession no. Z35780) showed homology to HAP1-encoded protein, and we have named this gene *APN2*.

Generation of yeast null mutations

Deletion mutations were generated in yeast by the gene replacement method (Rothstein 1991) using the *URA3* geneblaster. To construct a genomic deletion mutation of *APN1*, a 1.9-kb PCR product containing the *APN1* gene was cloned into pUC19, generating the plasmid pPM750. The region of *APN1* from the *Bgl*III site at nucleotide position +25 to the *Eco*RV site at position +1057 within the *APN1* ORF was replaced with the *URA3* geneblaster fragment. The resulting plasmid, pPM753, when cut with *Pvu*II results in a linear DNA fragment, incorporation of which in the yeast genome deletes *APN1* from nucleotide +30 to +1060 of the 1104-bp *APN1* ORF. To construct the *apn2* deletion generating plasmid, a 2.54-kb PCR product encompassing the *APN2* gene was generated and cloned into pUC19. The 1.37-kb *Bgl*III fragment within the *APN2* ORF was excised and replaced with the *URA3* geneblaster fragment. The *apn2Δ*-generating plasmid pPM838, when digested with *Bam*HI and *Sal*I, releases a linear DNA fragment, incorporation of which in the yeast genome deletes *APN2* from nucleotide +135 to +1505 of the 1563-bp *APN2* ORF. Linear deletion generating DNA was introduced into yeast strains by the lithium acetate method (Ito et al. 1983). Generation of genomic deletions was confirmed by PCR of genomic DNA. The *URA3* geneblaster fragment contains the *URA3* gene flanked by two direct repeats of the *Salmonella* *HisG* sequence. These repeats allow for recombination in yeast to excise the *URA3* gene (Alani et al. 1987). Loss of the *URA3* gene was selected for by plating cells on medium containing 5-fluoro-orotic acid (5-FOA).

Spontaneous forward mutation of *CAN1*^S

To measure the rates of spontaneous forward mutation at the *CAN1*^S locus, for each strain, 11 independent cultures were

grown in 500 μl of YPD, each starting from ~10 canavanine-sensitive cells. Cells were grown for 3 days at 30°C and subsequently plated onto synthetic complete (SC) medium lacking arginine but containing canavanine. Plates were incubated for 4–5 days before counting canavanine-resistant colonies. Rates of spontaneous forward mutation were determined by the method of the median (Lea and Coulson 1949). Each experiment was performed in duplicate.

MMS sensitivity and mutagenesis

All of the strains used for these experiments were derived from DBY747 that had been made *trp1Δ*, resulting in the strain EMY74.7 (*MATa his3-Δ1 leu2-3,-112 trp1Δ ura3-52*). For determining sensitivity to MMS and for measuring the rate of MMS-induced forward mutations at the *CAN1*^S locus, cells were grown overnight in YPD medium, sonicated to disperse clumps, washed, and resuspended in 0.05 M KPO₄ buffer at pH 7.0. Appropriate dilutions of MMS were added to 1-ml suspensions of cells adjusted to 1.5 × 10⁸ cells per ml. Samples were incubated in the presence of MMS with vigorous shaking at 30°C for 20 min. The reaction was terminated by the addition of 1 ml of 10% sodium thiosulfate. Appropriate dilutions of cells were plated on YPD for viability determinations and on synthetic complete medium lacking arginine but containing canavanine for determining the frequency of *can1*^r mutations. Plates were incubated at 30°C and counted after 3 and 4–5 days for viability and mutagenesis determinations, respectively.

Alkaline sucrose gradients

All strains for alkaline sucrose gradient sedimentation were derived from EMY74.7. ρ⁰ derivatives lacking mitochondrial DNA were obtained by ethidium bromide mutagenesis, resulting in the following isogenic strains used in these experiments: YRP276, *his3-Δ1 leu2-3,-112 trp1Δ ura3-52* ρ⁰; YRP210, *his3-Δ1 leu2-3,-112 trp1Δ ura3-52* ρ⁰ *apn1Δ*; YRP291, *his3-Δ1 leu2-3,-112 trp1Δ ura3-52* ρ⁰ *apn2Δ*; YRP292, *his3-Δ1 leu2-3,-112 trp1Δ ura3-52* ρ⁰ *apn1Δ apn2Δ*. Strains grown overnight at 30°C in SC medium containing 10 μg/ml of uracil and 10 μCi/ml [³H]uracil were collected by filtration, washed, and suspended in the same volume of SC containing 30 μg/ml of uracil. Cells were then incubated for 1 hr at 30°C to allow for depletion of the intracellular pool of [³H]uracil to occur. Cells were collected by filtration, washed, and suspended in 0.05 M KPO₄ buffer at pH 7.0, and incubated for 20 min with MMS at a final concentration of 0.1%. Cells were collected by filtration, washed, and resuspended in 3 ml of water. One milliliter of cells was used for the 0-hr sample and the other 2 ml of cells was diluted to 20 ml with YPD medium and incubated for an additional 1 or 2 hr to allow for repair to occur. Conversion of cells to spheroplasts, alkaline sucrose gradient sedimentation, and processing of samples were performed as described (Torres-Ramos et al. 1996), except that acid precipitation of alkali-hydrolyzed samples was carried out with 1 N HCl and 0.1 M sodium pyrophosphate rather than TCA.

Acknowledgments

This work was supported by grants GM19261, CA41261, and CA53791 from the National Institutes of Health, ES08547 from the National Institute of Environmental Health Sciences, and grant DEFGO3-93ER61706 from the Department of Energy.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked 'advertisement' in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Abate, C., L. Patel, F.J. Rauscher III, and T. Curran. 1990. Redox regulation of Fos and Jun DNA-binding activity in vitro. *Science* **249**: 1157–1161.
- Alani, E., L. Cao, and N. Kleckner. 1987. A method for gene disruption that allows repeated use of URA3 selection in the construction of multiply disrupted genes. *Genetics* **116**: 541–545.
- Altschul, S.F., W. Gish, W. Miller, E.W. Myers, and J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* **215**: 403–410.
- Barzilay, G., C.D. Mol, C.N. Robson, L.J. Walker, R.P. Cunningham, J.A. Tainer, and I.D. Hickson. 1995. Identification of critical active-site residues in the multifunctional human DNA repair enzyme HAP1. *Nat. Struct. Biol.* **2**: 561–568.
- Bjoras, M., A. Klungland, R.F. Johansen, and E. Seeberg. 1995. Purification and properties of the alkylation repair DNA glycosylase encoded *MAG* gene from *Saccharomyces cerevisiae*. *Biochemistry* **34**: 4577–4582.
- Chen, D.S., T. Herman, and B. Dimple. 1991. Two distinct human DNA diesterases that hydrolyze 3'-blocking deoxyribose fragments from oxidized DNA. *Nucleic Acids Res.* **19**: 5907–5914.
- Dimple, B. and L. Harrison. 1994. Repair of oxidative damage to DNA: Enzymology and biology. *Annu. Rev. Biochem.* **63**: 915–948.
- Gibbs, P.E.M., W.G. McGregor, V.M. Maher, P. Nisson, and C.W. Lawrence. 1998. A human homolog of the *Saccharomyces cerevisiae* *REV3* gene, which encodes the catalytic subunit of DNA polymerase ζ . *Proc. Natl. Acad. Sci.* **95**: 6876–6880.
- Gorman, M.A., S. Morera, D.G. Rothwell, E. de la Fortelle, C.D. Mol, J.A. Tainer, I.D. Hickson, and P.S. Freemont. 1997. The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. *EMBO J.* **16**: 6548–6558.
- Higgins, N.P., K. Kato, and B. Strauss. 1976. A model for replication repair in mammalian cells. *J. Mol. Biol.* **101**: 417–425.
- Ito, H., Y. Faulkuda, K. Murata, and A. Kimura. 1983. Transformation of intact yeast cells treated with alkali cations. *J. Bacteriol.* **153**: 163–168.
- Izumi, T. and S. Mitra. 1998. Deletion analysis of human AP-endonuclease: Minimum sequence required for the endonuclease activity. *Carcinogenesis* **19**: 525–527.
- Jayaraman, L., K.G.K. Murthy, C. Zhu, T. Curran, S. Xanthoudakis, and C. Prives. 1997. Identification of redox/repair protein Ref-1 as a potent activator of p53. *Genes & Dev.* **11**: 558–570.
- Johnson, A.W. and B. Dimple. 1988a. Yeast DNA 3'-repair diesterase is the major cellular apurinic/aprimidinic endonuclease: Substrate specificity and kinetics. *J. Biol. Chem.* **263**: 18017–18022.
- Johnson, A.W. and B. Dimple. 1988b. Yeast DNA diesterase for 3'-fragments of deoxyribose: Purification and physical properties of a repair enzyme for oxidative DNA damage. *J. Biol. Chem.* **263**: 18009–18016.
- Lawrence, C.W. and D.C. Hinkle. 1996. DNA polymerase ζ and the control of DNA damage induced mutagenesis in eukaryotes. *Cancer Surv.* **28**: 21–31.
- Lea, D.E. and C.A. Coulson. 1949. The distribution of the numbers of mutants in bacterial populations. *J. Genet.* **49**: 264–285.
- Lindahl, T. and B. Nyberg. 1972. Rate of depurination of native deoxyribonucleic acid. *Biochemistry* **11**: 3610–3617.
- Mol, C.D., C.-F. Kuo, M.M. Thayer, R.P. Cunningham, and J.A. Tainer. 1995. Structure and function of the multifunctional DNA-repair enzyme exonuclease III. *Nature* **374**: 381–386.
- Mozzherin, D.J., S. Shibutani, C.-K. Tan, K.M. Downey, and P.A. Fisher. 1997. Proliferating cell nuclear antigen promotes DNA synthesis past template lesions by mammalian DNA polymerase δ . *Proc. Natl. Acad. Sci.* **94**: 6126–6131.
- Nelson, J.R., C.W. Lawrence, and D.C. Hinkle. 1996a. Deoxycytidyl transferase activity of yeast *REV1* protein. *Nature* **382**: 729–731.
- . 1996b. Thymine-thymine dimer bypass by yeast DNA polymerase ζ . *Science* **272**: 1646–1649.
- Popoff, S.C., A.I. Spira, A.W. Johnson, and B. Dimple. 1990. Yeast structural genes (*APN1*) for the major apurinic endonuclease: Homology to *Escherichia coli* endonuclease IV. *Proc. Natl. Acad. Sci.* **87**: 4193–4197.
- Ramotar, D., S.C. Popoff, E.B. Gralla, and B. Dimple. 1991. Cellular role of yeast Apn1 apurinic endonuclease/3'-diesterase: Repair of oxidative and alkylation DNA damage and control of spontaneous mutation. *Mol. Cell. Biol.* **11**: 4537–4544.
- Rothstein, R. 1991. Targeting, disruption, replacement, and allele rescue: Integrative DNA transformation in yeast. *Meth. Enzymol.* **194**: 281–301.
- Roy, R., C. Brooks, and S. Mitra. 1994. Purification and biochemical characterization of recombinant *N*-methylpurine-DNA glycosylase of the mouse. *Biochemistry* **33**: 15131–15140.
- Sander, M. and D. Ramotar. 1997. Partial purification of Pde1 from *Saccharomyces cerevisiae*: Enzymatic redundancy for the repair of 3'-terminal DNA lesions and abasic sites in yeast. *Biochemistry* **36**: 6100–6106.
- Seeberg, E., L. Eide, and M. Bjoras. 1995. The base excision repair pathway. *Trends Biochem. Sci.* **20**: 391–396.
- Strauss, B.S. 1991. The 'A-rule' of mutagen specificity: A consequence of DNA polymerase bypass of non-instructional lesions? *BioEssays* **13**: 79–84.
- Torres-Ramos, C.A., B.L. Yoder, P.M.J. Burgers, S. Prakash, and L. Prakash. 1996. Requirement of proliferating cell nuclear antigen in *RAD6*-dependent postreplicational DNA repair. *Proc. Natl. Acad. Sci.* **93**: 9676–9681.
- Walker, L.J., C.N. Robson, E. Black, D. Gillespie, and I.D. Hickson. 1993. Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. *Mol. Cell. Biol.* **13**: 5370–5376.
- Wallace, S. 1997. Oxidative damage to DNA and its repair. In *Oxidative stress defenses* (ed. J.G. Scandalios), pp. 49–90. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Winters, T.A., W.D. Henner, P.S. Russell, A. McCullough, and T.J. Jorgensen. 1994. Removal of 3'-phosphoglycolate from DNA strand-break damage in an oligonucleotide substrate by recombinant human apurinic/aprimidinic endonuclease 1. *Nucleic Acids Res.* **22**: 1866–1873.
- Xanthoudakis, S. and T. Curran. 1992. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. *EMBO J.* **11**: 653–665.
- Xanthoudakis, S., G. Miao, F. Wang, Y.-C.E. Pan, and T. Curran. 1992. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. *EMBO J.* **11**: 3323–3335.
- Xanthoudakis, S., G.G. Miao, and T. Curran. 1994. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. *Proc. Natl. Acad. Sci.* **91**: 23–27.
- Xanthoudakis, S., R.J. Smeyne, J.D. Wallace, and T. Curran. 1996. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. *Proc. Natl. Acad. Sci.* **93**: 8919–8923.

Identification of *APN2*, the *Saccharomyces cerevisiae* homolog of the major human AP endonuclease *HAP1*, and its role in the repair of abasic sites

Robert E. Johnson, Carlos A. Torres-Ramos, Tadahide Izumi, et al.

Genes Dev. 1998, **12**:

Access the most recent version at doi:[10.1101/gad.12.19.3137](https://doi.org/10.1101/gad.12.19.3137)

References

This article cites 36 articles, 16 of which can be accessed free at:
<http://genesdev.cshlp.org/content/12/19/3137.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).